- Home
- PSLV vs GH Comparison
PSLV vs GH Comparison
Compare PSLV & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSLV
- GH
- Stock Information
- Founded
- PSLV N/A
- GH 2011
- Country
- PSLV
- GH United States
- Employees
- PSLV N/A
- GH N/A
- Industry
- PSLV
- GH Medical Specialities
- Sector
- PSLV
- GH Health Care
- Exchange
- PSLV NYSE
- GH Nasdaq
- Market Cap
- PSLV 5.1B
- GH 4.3B
- IPO Year
- PSLV N/A
- GH 2018
- Fundamental
- Price
- PSLV $10.11
- GH $34.64
- Analyst Decision
- PSLV
- GH Strong Buy
- Analyst Count
- PSLV 0
- GH 15
- Target Price
- PSLV N/A
- GH $39.93
- AVG Volume (30 Days)
- PSLV N/A
- GH 1.5M
- Earning Date
- PSLV N/A
- GH 11-06-2024
- Dividend Yield
- PSLV N/A
- GH N/A
- EPS Growth
- PSLV N/A
- GH N/A
- EPS
- PSLV N/A
- GH N/A
- Revenue
- PSLV N/A
- GH $692,256,000.00
- Revenue This Year
- PSLV N/A
- GH $32.23
- Revenue Next Year
- PSLV N/A
- GH $16.90
- P/E Ratio
- PSLV N/A
- GH N/A
- Revenue Growth
- PSLV N/A
- GH 29.20
- 52 Week Low
- PSLV N/A
- GH $15.81
- 52 Week High
- PSLV N/A
- GH $38.53
- Technical
- Relative Strength Index (RSI)
- PSLV 40.18
- GH 58.28
- Support Level
- PSLV $10.16
- GH $34.20
- Resistance Level
- PSLV $10.28
- GH $36.24
- Average True Range (ATR)
- PSLV 0.12
- GH 1.40
- MACD
- PSLV -0.02
- GH -0.54
- Stochastic Oscillator
- PSLV 1.44
- GH 12.70
About PSLV SPROTT PHYSICAL SILVER TRUST
Sprott Physical Silver Trust is a closed-end mutual fund trust, created to invest and hold substantially all of its assets in physical silver bullion. The Trust seeks to provide a secure, convenient, and exchange-traded investment alternative for investors interested in holding physical silver bullion without the inconvenience that is typical of a direct investment in physical silver bullion. The Trust achieves its objective by investing mainly in long-term holdings of unencumbered, fully allocated, physical silver bullion and does not speculate with regard to short-term changes in silver prices.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.